Browse Products by Therapy

Clindamycin in 0.9% Sodium Chloride Injection, 300mg/50mL in GALAXY Plastic Container. Liquid Premix.

Email | Print

SKU: 2G3455

Clindamycin in 0.9% Sodium Chloride Injection, 300mg/50mL in GALAXY Plastic Container. Liquid Premix. Please refer to full Prescribing Information, including Boxed Warning. NDC 0338-9545-50.

Product information last updated Apr-22-2021

Product Characteristics

Trademark: GALAXY is a trademark of Baxter International Inc., and it's subsidiaries.
Latex: Not Made with Natural Rubber Latex
Container Type: GALAXY
PVC: Non-PVC
DEHP: Non-DEHP
Volume: 50 ML
Drug Class: Anti-Infective
Dosage Form: Liquid
Diluent: Sodium Chloride
Strength: 300 mg/50 mL
Concentration: 6 mg/mL
Shelf Life from manufacture: 18 months
Contains Preservative: No
Storage Recommendations: It is recommended that GALAXY plastic containers be stored at 20°C to 25°C (68°F to 77°F) excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Avoid temperatures above 30°C.
Rx Only: Yes
Package Insert Link: www.baxterpi.com/pi-pdf/C(..)

Carton

Length: 11.94 IN
Width: 5.88 IN
Height: 2.5 IN
Volume: 0.1 FC
Weight: 3.33 LB
Pack Factor: 24

Reimbursement Information

HCPCS Code HCPCS Descriptor
S0077 Injection, clindamycin phosphate, 300mg
A4216 STERILE WATER, 0.9% Sodium Chloride AND/OR DEXTROSE DILUENT/FLUSH, 10 ML
Medication Delivery Reimbursement Hotline 888-338-0001
Information Source: CMS
Disclaimer: The coverage, coding, and payment information included in this guide has been compiled from various resources for informational use as a tool to assist providers with reimbursement issues. This information is current as of 3/31/2008; however this information is subject to change and should not be construed as legal advice. Providers should exercise independent clinical judgment when selecting codes and submitting claims to accurately reflect services rendered to individual patients. Baxter Healthcare Corporation does not guarantee success in obtaining insurance payments. Providers are encouraged to contact third-party payors for specific information on their coverage, coding, and payment policies.